Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals Inc. weaves a distinctive narrative within the realm of specialty pharmaceuticals, primarily zeroing in on the development and commercialization of products that address unmet medical needs in central nervous system (CNS) diseases. Founded in 2005 and headquartered in Rockville, Maryland, the company has become a nimble player in the pharmaceutical landscape, leveraging its expertise in product development to create a portfolio that caters to a range of CNS conditions, including epilepsy, migraine, attention-deficit/hyperactivity disorder (ADHD), and bipolar disorder. By focusing on these complex and often challenging areas, Supernus not only pushes the envelope of pharmaceutical innovation but also aligns its mission closely with improving quality of life for patients enduring these conditions.
Financially, Supernus drives its revenue through both its proprietary portfolio and strategic partnerships that expand its market reach. Central to its business model is the commercialization of FDA-approved medications such as Trokendi XR and Qelbree, which cater to specific patient needs within the CNS domain. The company's growth is augmented by an adept blend of internal research & development and acquisitions, enabling it to enhance its pipeline and expand its therapeutic offerings. Partnerships and collaborations with other pharmaceutical entities elevate its market penetration, while a solid sales and distribution network ensures its products efficiently reach healthcare providers and patients. This strategic approach allows Supernus to maintain a robust revenue stream while steadily investing in future drug development programs, fostering long-term growth and sustainability within the competitive pharmaceutical sector.
Supernus Pharmaceuticals Inc. weaves a distinctive narrative within the realm of specialty pharmaceuticals, primarily zeroing in on the development and commercialization of products that address unmet medical needs in central nervous system (CNS) diseases. Founded in 2005 and headquartered in Rockville, Maryland, the company has become a nimble player in the pharmaceutical landscape, leveraging its expertise in product development to create a portfolio that caters to a range of CNS conditions, including epilepsy, migraine, attention-deficit/hyperactivity disorder (ADHD), and bipolar disorder. By focusing on these complex and often challenging areas, Supernus not only pushes the envelope of pharmaceutical innovation but also aligns its mission closely with improving quality of life for patients enduring these conditions.
Financially, Supernus drives its revenue through both its proprietary portfolio and strategic partnerships that expand its market reach. Central to its business model is the commercialization of FDA-approved medications such as Trokendi XR and Qelbree, which cater to specific patient needs within the CNS domain. The company's growth is augmented by an adept blend of internal research & development and acquisitions, enabling it to enhance its pipeline and expand its therapeutic offerings. Partnerships and collaborations with other pharmaceutical entities elevate its market penetration, while a solid sales and distribution network ensures its products efficiently reach healthcare providers and patients. This strategic approach allows Supernus to maintain a robust revenue stream while steadily investing in future drug development programs, fostering long-term growth and sustainability within the competitive pharmaceutical sector.
Record Revenue: Supernus reported record total revenue of $719 million for 2025, driven by strong growth from its four core products.
Growth Product Momentum: Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO together accounted for 76% of Q4 revenue, marking a shift from legacy products.
ONAPGO Supply Resolved: Supply constraints for ONAPGO have been addressed, and new patient initiations have resumed, with the current supplier covering all 2026 guidance needs.
ZURZUVAE Uptake: ZURZUVAE saw rapid prescription growth with a 187% year-over-year increase in Q4 sales and high repeat prescriber rates.
Qelbree Delivers: Qelbree net sales topped $300 million, up 26%, with double-digit prescription growth across adult and pediatric populations.
2026 Outlook: Management guided 2026 total revenue of $840–870 million and expects operating income to range from breakeven to a loss of $30 million.
Strategic Focus: Supernus remains focused on CNS and women's health, pursuing additional revenue-generating or late-stage pipeline assets.
